Pharmacotheraphy for alcohol dependence: Anticraving medications for relapse prevention

Yonsei Medical Journal

Volumn 47, Issue 2, 2006, Pages 167-178

  Jung, Young Chul ^a   Namkoong, Kee ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Acamprosate; Alcohol dependence; Naltrexone; Pharmacotherapy

Indexed keywords

4 AMINOBUTYRIC ACID; ACAMPROSATE; ADENOSINE; ALCOHOL; AMFEBUTAMONE; CANNABINOID RECEPTOR; DISULFIRAM; DOPAMINE; GLUTAMIC ACID; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NALTREXONE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; ONDANSETRON; OPIATE; OPIATE ANTAGONIST; PLACEBO; RITANSERIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; DRUG DERIVATIVE; DRUGS USED IN THE TREATMENT OF ADDICTION; GLUTAMINE; N METHYLASPARTIC ACID; OPIATE RECEPTOR; TAURINE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLICS ANONYMOUS; ALCOHOLISM; ANXIETY DISORDER; AVERSION; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; FLUSHING; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; HEADACHE; HEART INFARCTION; HEART PALPITATION; HEREDITY; HUMAN; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHARMACOGENOMICS; PREDICTION; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RELAPSE; RESPIRATION DEPRESSION; REVIEW; REWARD; SOCIAL PSYCHOLOGY; SOMNOLENCE; TREATMENT OUTCOME; UNITED STATES; WITHDRAWAL SYNDROME; BIOLOGICAL MODEL; DRUG ANTAGONISM; GENETICS; METABOLISM; NERVE CELL; RECURRENT DISEASE;

ALCOHOL DETERRENTS; ALCOHOLISM; DISULFIRAM; GAMMA-AMINOBUTYRIC ACID; GLUTAMINE; HUMANS; MODELS, BIOLOGICAL; MODELS, NEUROLOGICAL; N-METHYLASPARTATE; NALTREXONE; NEURONS; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; RECURRENCE; TAURINE;

EID: 33646181801     PISSN: 05135796     EISSN: 05135796     Source Type: Journal    
DOI: 10.3349/ymj.2006.47.2.167     Document Type: Review

References (78)

1. Morse RM, Flavin DK. The definition of alcoholism. The joint Committee of the National Council on Alcoholism and Drug Dependency and the Amercian Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism. JAMA 1992;268:1012-4.
2. Jung YC, Namkoong K. Two alcoholisms: Abuse and Dependence: Nosology issues from the epidemiological studies of alcoholism in Korea. Psychiatr Invest 2005;2: 40-52.
3. Cho MJ, Hahm BJ, Kim JK, Park KK, Chung EK, Suh TW, et al. Korean Epidemiologic Catchment Area (KECA) Study for Psychiatric Disorders: Prevalence of Specific Psychiatric Disorders. J Korean Neuropsychiatr Assoc 2004;43:470-80.
4. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996;91:1773-96.
5. Swift RM. Drug therapy in alcohol dependence. N Engl J Med 1999;340:1482-90.
6. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. Am J Health Syst Pharm 2004; 61:2272-388.
7. Williams SH. Medications for treating alcohol dependence. Am Fam Physician 2005;72:1775-80.
8. O'Brien CP. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005;162:1423-31.
9. Gordis E. The neurobiology of alcohol abuse and alcoholism: building knowledge, creating hope. Drug Alcohol Dependence 1998;51:9-11.
10. Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyytia P, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998;22: 3-9.
11. Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 1985;348:201-03.
12. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993;18:247-91.
13. Benjamin D, Grant E, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993;621:137-40.
14. Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of GABAA receptors in the acute and chronic effects of ethanol. Psychopharmacology 1998;139:2-19.
15. Quertemont E, Brabant C, De Witte P. Acamprosate reduces context-dependent ethanol effects. Psychopharmacology 2002;164:10-8.
16. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60:92-9.
17. Garbutt JC, West SI, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999;281:1318-25.
18. Kiefer F, Mann K. New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. Eur J Pharmacol 2005;526:163-71.
19. Fuller RK, Brachey I, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A Veterans Administration Cooperative Study. JAMA 1996;256:1449-55.
20. Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropyschopharmacol 2003;13:469-75.
21. Savin S. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G.et al. Clinical pharmacokinetics of acamprosate. Clin. Pharmacokinet. 1998;35:331-45.
22. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-80.
23. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992;49:881-7.
24. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001;25:1335-41.
25. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001;36:544-52.
26. Srisurapanont M, Jarusuraisin N. Opioid antagonist for alcohol dependence. Cochrane Database Syst Rev 2002; (2):CD001867.
27. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA; Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Eng J Med 2001;345:1734-9.
28. Liu X, Weiss F. Addictive effect of stress and grug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-rel easing factor and opioid mechanism. J Neurosci 2002;22:7856-61.
29. Balladin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003;27:1142-9.
30. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy of outpatients alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999;156:1758-64.
31. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000;35:587-93.
32. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25:1634-47.
33. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005;293:1617-25.
34. Sinclair JD. Evidence about the use of naltrexone for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001;36:2-10.
35. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2005;8: 267-80.
36. Croop RS. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1997;54:1130-5.
37. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in maintaining abstinence in alcohol dependent individuals: results of meta-analysis. Alcohol Clin Exp Res 2004;28:51-63
38. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo controlled study in alcohol dependence. Arch Gen Psychiatry 1996;53:673-80.
39. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-42.
40. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double blind, placebo controlled study. Alcohol Alcohol 2003;38:135-41.
41. Keifer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60:92-9.
42. Kiefer F, Andersohn F, Otte C, Wolf K, Jahn H, Wiedemann K. Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence. Acta Neuropsychiatr 2004;16:233-8.
43. Kiefer F, Wiedemann K. Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol 2004;39:542-7.
44. COMBINE study group. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence (the COMBINE study): rationale and methods. Alcohol Clin Exp Res 2003;27:1107-22.
45. Ooteman W, Verheul R, Naassila M, Daoust M, Schippers GM, Koeter MWJ, et al. Patient-treatment matching with anti-craving medications in alcohol dependent patients: A review on phenotypic, endophenotypic and genetic indicators. J Substance Use 2005;10:75-96.
46. Anton RF. What is craving? Models and implications for treatment. Alcohol Res Health 1999;23:165-73.
47. Verheul R, van den Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 1999;34:197-222.
48. Volpicelli JR. Naltrexone in the alcohol dependence. Lancet 1995;346:456.
49. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brein CP, et al. Predicting treatment response to naltrexone: The influence of craving and family history. Am J Addiction 2001;10:258-68.
50. Palfai L Davidson D, Swift R. Influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome experiences. Exp Clin Psychopharmacol 1999;7:266-73.
51. Lesch OM, Walter H. Subtypes of alcoholism and their role in therapy. Alcohol Alcohol 1996;31:63-7.
52. Verheul R, Lehert P, Geerlings PJ, Koeter MW, Van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology 2005;178:167-73.
53. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673-80.
54. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamic-pituitary-adrenocortical axis. Psychopharmacology(Berl) 2002;160:19-29.
55. Heath AC. Genetic influences on alcoholism risk: a review on adoption and twin studies. Alcohol Health Res World 1995;19:166-71.
56. King AC, Schluger J, Gunduz M, Borg L, Perret G, Ho A, et al. Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotranformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology 2002;26: 778-88.
57. Lichtermann D, Franke P, Maier W, Rao ML. Pharmacogenetics and addiction to opiates. Eur J Pharmacol 2000;410:269-79.
58. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Vopicelli JR, et al. A functional polymerphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003;28:1546-52.
59. Kim SG, Kim CM, Kang DH, Kim YJ, Byun WT, Kim SY, et al. Association of functional opioid receptor genotypes with alcohol dependence in Koreans. Alcohol Clin Exp Res 2004;28:986-90.
60. Gorelick DA, Paredes A. Effects of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992;16:261-5.
61. Kabel DI, Petty F. A placebo-controlled, double-blind study of fluozetine in severe alcohol dependenc: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 1996;20:780-4.
62. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995;152:391-7.
63. Janiri L, Gobbi G, Mannelli P, Pozzi G, Serretti A, Tempesta E. Effects of fluoxetine at antidereesant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol 1996;11:109-17.
64. Pettinati HM, Volpocelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001;21:143-53.
65. Roy A. Placebo-controlled study of setaline in depressed recently abstinent alcoholics. Biel Psychiatry 1998;44:633-7.
66. Johnson BA, Jansinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, et al. Ritanserin in the treatment of alcohol dependence-a multi-center clinical trial. Psychopharmacology 1996;128:206-15.
67. Wiesbeck GA, Weijers JG, Chick J, Naranjo CA, Boening J. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled, double-blind internaltional multi-center trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 1999;23: 230-5.
68. Malec TS, Malec EA, Dongier M. Efficacy of bupropion in alcohol dependence: a review. Alcohol Clin Exp Res 1996;20:853-80.
69. LeMarquand D, Pihl RO, BenKelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry 1994;36:326-37.
70. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38:1083-152.
71. Johnson BA, Cowen PJ. Alcohol induced reinforcement: dopamine and 5-HT3 receptor interactions in animals and humans. Drug Dev Res 1993;30:153-69.
72. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1995;18:879-85.
73. Johnson BA, Roache JD, Javors MA, Diclemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000;284:963-71.
74. Fils-Aime ML, Eckardt MJ, George DT, Brown GL, Mefford I, Linnoila M. Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels that late-onset alcoholics. Arch Gen Psychiatry 1996;53:211-6.
75. Swann AC, Johnson BA, Cloninger CR, Chen YR. Relationships of plasma tryptophan availability to course of illness and clinical features of alcoholism: a preliminary study. Psychopharmacology(Berl) 1999;143:380-4.
76. Book SW, Myrick H. Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investing Drugs 2005;14:371-6.
77. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 2004;61:905-12.
78. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003;361:1677-85.